pharma news

News

Sanofi gives up on amlitelimab in atopic dermatitis

Sanofi has stopped development of anti-OX40L drug amlitelimab in atopic dermatitis, a major blow to what was once viewed as a 'pipeline-in-a-product'.

News

Re-rostered FDA committee backs peptide compounding

Against the advice of FDA staff scientists, an advisory committee has narrowly voted in support of looser restrictions on compounded peptides.

News

J&J's multiple myeloma duo aces phase 3 trial

Two of Johnson & Johnson's multiple myeloma bispecifics, Tecvayli and Talvey, have dramatically improved survival when used as a second-line regimen.

News

Dexcom is first to join FDA/CMS health tech pilot

The FDA has named Dexcom as the first company to take part in its TEMPO pilot, which aims to bring digital health tech to patients more quickly.

News

Lilly plans Q1 2027 filing for obesity triple retatrutide

Armed with new pivotal trial results, Eli Lilly is preparing to file for approval of its triple-acting weight-loss therapy, retatrutide, next year.

News

EU clears AZ's SERD camizestrant, as FDA review drags on

AstraZeneca's new breast cancer therapy Etcamah claims landmark frontline approval in the EU, but its prospects in the US are less certain.

Sanofi gives up on amlitelimab in atopic dermatitis

Re-rostered FDA committee backs peptide compounding

J&J's multiple myeloma duo aces phase 3 trial

Dexcom is first to join FDA/CMS health tech pilot

Lilly plans Q1 2027 filing for obesity triple retatrutide

EU clears AZ's SERD camizestrant, as FDA review drags on

Amgen's Horizon buyout delivers Sjögren's disease win

Discover a new era of healthcare panel engagement: Grounded ...

pharma news

Editor's Picks